不同海拔高原官兵亚健康状态的调查研究

目的：调查研究不同海拔高度官兵的亚健康状态。方法抽取4种海拔(1500、3700、5380、5390 m)的高原边防和后勤官兵共344名，进行康奈尔健康量表测评。测评结果建立数据库，用SPSS 17.0进行数据分析，测量相关数据的前后变化。结果数据结果显示不同海拔高度的官兵健康状况随海拔高度的变化存在差异，而高原边防和后勤官兵的整体健康状况差异不大。结论高原官兵要改善亚健康状态，应该从思想教育，心理调整和保障制度等多方面着手，切实保障官兵健康和提高部队战斗力。     

1 alpha(OH)D3 (ETALPHA) treatment and receptor studies in 16 patients with chronic and myeloproliferative disorders

10 patients with CLL and 2 with CML were treated with gradually increasing doses of 1 alpha(OH)D3, up to 4 micrograms daily during 6 wk. 3 patients with preleukemia and 1 with myelofibrosis were treated with 2 micrograms daily of 1 alpha(OH)D3 for a prolonged period up to 17 wk. The treatment with 1 alpha (OH)D3 did not result in changes of disease parameters in any of the patients under study. Receptor studies for 1,25(OH)2D3 were performed in 8 CLL patients and revealed only 1 patient with increased specific receptor binding capacity. The maximum tolerable dose of 1 alpha(OH)D3 varied individually, but was in the range of 2-4 micrograms daily.     

An unusual case of chronic myelocytic leukemia characterized by a conspicuous tissue infiltration treated with leukapheresis

Summary An unusual case of chronic myelocytic leukemia (CML) is described that presented leukocytosis at onset (720×10⁹/l), symptoms of stasis, organomegaly, and a conspicuous infiltration of leukemic cells from the pelvis to the right popliteal cavity. As initial therapy and in addition to chemotherapy, six therapeutic leukapheresis treatments (TL) were performed and the patient showed dramatic symptomatic improvement with reduction in leukocytosis (97×10⁹/l), organomegaly, and tissue infiltration.     

运用Cox模型和Sokal,Hasford积分系统对慢性髓细胞白血病患者的预后分析

本研究分析影响慢性髓细胞白血病（CML）患者预后的危险因素。采用回顾性研究分析204例CML患者的临床及实验室检查资料，用Kaplan—Meier法绘制生存曲线，用Logrank检验比较生存率，运用Cox回归模型进行单因素及多因素分析，并分别计算Sokal，Hasford积分。结果表明：204例患者中位生存时间为50（32—65）月，5年生存率32．3％（95％CI，23．7％-42．6％）。干扰素组与羟基脲组的中位生存时间分别为56（41—67）月和41（19—56）月，5年生存率分别为45．4％（95％CI，37．5％-54．2％）和26．8％（95％CI，21．6％-33．3％）（P〈0．001）。经Cox回归分析，Ph染色体阴性、乳酸脱氢酶含量增高、外周血嗜碱性粒细胞≥10％、出现有核红细胞、骨髓原粒细胞≥4％、骨髓原始＋早幼粒细胞≥10％和红细胞压积降低是CML预后不良的危险因素，而治疗方法也是影响CML预后的重要因素。羟基脲组经Sokal积分检验，高危组占72．9％，中危组占21．5％，而低危组占5．6％，中位生存时间分别为34（23—49）月、43（32—58）月、50（38—62）月；干扰素组经Hasford积分检验，高危组占17．6％，中危组占25．1％，低危组占57．3％，中位生存时间分别为44（33—57）月、56（45—70）月和66（52—76）月。结论：Ph染色体、乳酸脱氢酶含量、红细胞压积、外周血嗜碱性粒细胞、出现有核红细胞、骨髓原始和早幼粒细胞以及治疗方法是影响CML预后的重要因素。以Sokal积分系统评价羟基脲组患者不能很好区分危险组，而Hasford积分系统评价干扰素组患者，能够区分危险组。     

慢性粒细胞白血病骨髓细胞体外培养净化作用实验研究

目的 :采用 FISH方法直接在干细胞水平对慢性粒细胞白血病 (CML )患者自体骨髓体外培养前后的间期细胞进行 bcr/abl融合基因检测 ,从而探讨 CML 骨髓细胞体外培养对自体骨髓移植物的净化作用。方法 :分离初治的慢性期 Ph+ CML 7例骨髓单个核细胞 (MNCs) ,体外培养 10 d,用免疫磁珠 (MACS)富集培养前后的 CD34+ 细胞 ,通过流式细胞仪检测培养前后 MNCs中 CD34+ 干细胞比例 ,然后用 FISH方法检测其中 bcr/abl融合基因 ,同时分别用正常人细胞及 K5 6 2细胞株作阴性及阳性对照。结果 :(1) 7例患者骨髓细胞培养前后 CD34+ 细胞中 bcr/abl融合基因平均检出率分别为 85 .3%± 4 .9%和 78%± 5 .1% ,有统计学意义 (P<0 .0 5 ) ,(2 )培养前培养体系中 CD34+ 细胞数量为 (6 .0 6 0± 1.5 6 4 )× 10 5个 ,培养后体系中的 CD34+细胞数量为 (5 .974± 1.4 2 4 )× 10 5个 ,两者无明显差异 (P>0 .0 5 )。 (3)在对照组中假阳性率为 2 .5 % ,假阴性率为 2 %。结论 :自体骨髓细胞体外培养对 CML 病人的骨髓肿瘤细胞有一定程度的净化作用 ;FISH技术直接在干细胞水平检测 bcr/abl融合基因 ,且能定量分析 ,较传统方法更适合对骨髓净化进行评价 ,为骨髓净化提供了一种更方便、可靠的评定方法     

Recombinant human interferon-alpha induced cytoreduction in chronic myelogenous leukemia

Summary Fourteen patients with Ph'-chromosome positive chronic myelogenous leukemia (CML) in first chronic phase were treated with recombinant interferon-_2c. Interferon-_2c 5 to 10×10⁶ units s.c. was given for 12 weeks as an induction therapy. Maintenance treatment consisted of interferon-_2c 5 × 10⁶ units twice weekly s.c.. Two patients (14%) attained a complete clinical remission and 6 (43%) a partial remission, 3 of whom developed progressive disease during maintenance therapy. A complete disappearance of Ph'-chromosome was achieved in 1 patient. All patients had a more than 45% initial decline of the leukocyte count. Four out of ten patients with an initially enlarged spleen demonstrated reduction in spleen size. Influenza-like symptoms, anorexia, nausea, weight loss and fatigue were common side effects. Interferon-alpha is active in CML but additional clinical investigations are warranted to assess more precisely the therapeutic value of the interferons in this disease.     

Monoclonal antibodies against human granulocytes and myeloid differentiation antigens

Monoclonal antibodies (MCA) were obtained by immunizing BALB/c mice with 99% pure granulocytes from normal donors or with a whole leukocyte suspension obtained from a chronic myelogenous leukemia (CML) patient, and then fusing the mouse spleen cells with a 315–43 myeloma cell clone. Four MCA were selected and studied using ELISA, immunofluorescence, cytotoxicity assays, and FACS analysis. Antibodies 80H.1. 80H.3. and 80H.5 (from normals) and 81H.1 (from CML) detected antigens expressed on neutrophils. Antibodies 80H.1 and 80H.3 (lgG) also reacted with monocytes but not with other blood cell subsets. Antibodies 80H.5 and 81H.1 (lgM) were cytotoxic and reacted strongly with most of the cells of the neutrophil maturation sequence. i.e., myeloblasts, promyelocytes, myelocytes, and mature granulocytes. Antibodies 80H.5 and 81H.1 also inhibited BFU-GM and CFU-E. Antigens recognized by 80H.3. 80H.5, and 81H.1 were expressed both on a proportion of cells from HL.60, KG.1, ML.1, and K562 myeloid cell lines, and on a proportion of blast cells isolated from patients with acute myelogenous leukemia. They were not found on lymphoid cell lines or lymphoid leukemia cells. These MCA recognize either late differentiation antigens expressed on mature neutrophils and monocytes (80H.1 and 80H.3) or early differentiation antigens (80H.5 and 81H.1) specific to the granulocytic lineage. They may be useful for a better definition of those antigens specific to hematopoietic stem cells and their relationship with normal or neoplastic hematopoiesis.     

180例慢性粒细胞白血病骨髓染色体畸变及意义

目的　研究骨髓染色体畸变与慢性粒细胞白血病 (慢粒 )不同病期的相关性及其临床意义。方法　采取新鲜骨髓 ,进行短期培养 (48小时或 12小时预加秋水仙素培养 )制备染色体标本 ,分析 180例慢粒患者慢性期、加速期、急变期骨髓染色体的变异情况。结果　 180例慢粒患者 ,其中 16 4例Ph染色体阳性 (Ph ) ,占 91 1% ;16例Ph染色体阴性(Ph - ) ,占 8 9%。慢性期 133例Ph ,占总数的 73 9% ;加速期 9例Ph ,占总数 5 0 % ;急变期 2 2例Ph ,占总数12 2 %。 16 4例Ph 慢粒患者中 2 5例 (15 2 % )伴有额外染色体异常 ,其中慢性期占 4 2 7%、加速期占 2 4 %、急变期占8 5 3%。结果表明随着病情的进展 ,Ph 阳性率明显增高 ,其它染色体异常率也明显增高。结论　骨髓染色体畸变与慢粒白血病的病程进展、疾病预后有着十分重要的相关性 ,随着病情的演变 ,骨髓染色体畸变趋于复杂化。进行染色体分析对临床诊断及治疗慢粒具有十分重要的指导意义。     

A human B cell differentiation antigen selectively expressed on mature B cells identified by a monoclonal antibody (HB-2)

A monoclonal IgM antibody (HB-2), produced against a membrane antigen on the Raji, B cell line, reacted by indirect immunofluorescence with 2 to 40% of lymphoblasts from the B cell lines, Raji, Daudi, SN-1036, and SB but not with other types of cell lines, including pre-B, myeloid, melanoma, or T cells. HB-2 antibody reacted with 10 ± 3% of normal blood mononuclear cells, and was unreactive with monocytes, granulocytes, platelets, or erythrocytes. Two-color immunofluorescence revealed that HB-2 antigen expression was confined to cells bearing surface Ig. An interesting finding was the fact that 25% of plasmablasts induced by pokeweed mitogen also expressed the HB-2 antigen. However, pre-B and plasma cells from normal bone marrow did not express the HB-2 antigen either on their membrane surface or in their cytoplasm. Analysis of 85 leukemias revealed that the HB-2 antigen was expressed on acute and chronic B cell leukemias and Burkitt's lymphomas, but not on malignacies of pre-B, T, myelocytic, or plasma cells. The results suggest that expression of the HB-2 antigen is confined to mature B cells.     

Cytotoxic effector cells against HLA antigens in strong linkage disequilibrium: identification of a strong,new, CML determinant

Three sets of cytotoxic effector cells were generated against the A1, B8, DR3 haplotype using haptoidentical individuals in three different families. The three sets of effector cells generated against this haplotype showed excellent reproducibility testing, strong cytotoxicity against their specific targets, low autologous kill, and segregation with the sensitizing haplotype within the family. When tested against a panel of cells bearing all combinations the A1, B8. DR3 antigens, a hierarchy of contribution of the individual HLA antigens as CML target determinants was seen. A new strong target cell determinant was identified by cytotoxicity with one of the effector cells not explicable in terms of the A1, B8, DR3 antigens or known HLA cross-reactivity. A family study demonstrated that this determinant clearly segregates with HLA. The success of this approach in defining new CML determinants may result from the generation of effector cells across a single haplotype in strong linkage disequilibrium or from the presentation of CML determinants in the context of self.